Understanding how ovarian cancer responds to chemotherapy
Strategies for discerning chemotherapy response and resistance in ovarian cancer
This study is looking into why some women with high-grade serous ovarian cancer don’t respond well to standard chemotherapy, hoping to find early signs in their tumor cells that can help predict how well treatments will work, so that future therapies can be more personalized and effective.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Systems Biology NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10512982 on NIH RePORTER |
What this research studies
This research investigates the reasons why some ovarian cancer patients do not respond to standard chemotherapy treatments. It focuses on high-grade serous ovarian cancer, the most common and deadly form of ovarian cancer, and aims to identify early molecular changes in tumor cells that could predict treatment outcomes. By analyzing how these cancer cells react to chemotherapy at a molecular level, the study seeks to develop better predictive models for patient responses, potentially leading to more personalized treatment strategies. Patients may be monitored for their responses to existing treatments to gather data that could improve future therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with high-grade serous ovarian cancer who are undergoing chemotherapy.
Not a fit: Patients with ovarian cancer types other than high-grade serous or those who are not currently receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for ovarian cancer patients, reducing unnecessary toxicity from ineffective therapies.
How similar studies have performed: While there have been advancements in cancer genomics, the specific approach of identifying early-stage molecular changes in response to chemotherapy in ovarian cancer is relatively novel and has not been extensively tested.
Where this research is happening
Seattle, United States
- Institute for Systems Biology — Seattle, United States (Active)
Researchers
- Principal investigator: Wei, Wei — Institute for Systems Biology
- Study coordinator: Wei, Wei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.